adis journals overview - springer · the adis publishing heritage the adis journals brand has...
Post on 29-Sep-2018
233 Views
Preview:
TRANSCRIPT
Adis JournalsOverview
The Adis publishing heritageThe Adis Journals brand has evolved over
40 years to become synonymous with
current, comprehensive and objective
journal publishing, with a strong specialism
in pharmacology and pharmacotherapy.
Adis has proved that acute customer focus
can be achieved without compromising
the highest ethical publishing standards,
including rigorous independent peer
review. Adis Journals endorses the ICMJE
guidelines and is a member of COPE,
observing their Code of Conduct and Best
Practice Guidelines for Journal Editors.
Publishing research at every stage of the drug lifecycleCovering all aspects of the drug development
continuum from bench to bedside, Adis
Journals are a unique must-have resource for
researchers, clinicians, clinical pharmacists,
clinical pharmacologists, teachers, students,
and anyone with an interest in drug therapy
and pharmacology.
The Adis portfolio offers a wide range of
specialist titles publishing a complementary
blend of original research, independent
Adis Drug Evaluations and invited reviews.
Adis Editors possess great insight into the
trends within their speciality areas, and are
committed to recognizing and meeting the
needs of their readership.
Most Adis journals are indexed in MEDLINE
and have an international following of
paid subscribers.
Key features The following elements of the Adis Journals
program have been refined over 4 decades:
Strong customer service ethic
Adis’ publishing team takes great pride in the
speed and quality of the customer service they
provide. With offices in every major market
around the world, there is always a local Adis
representative available to provide a local
language service.
Cascading peer review
If a submitted article is rejected by an Adis
journal Editor based on peer-review comments,
those comments can be passed on to the Editor
of another relevant Adis journal and further
peer review may not be necessary.
Adis Open Access
9 An option to publish
any submitted original
research article under
an open access license
9 Available for any Adis
journal that publishes
original research articles
9 Articles are peer reviewed and must meet
the journal’s usual acceptance criteria
9 Journal Editors are blinded to the open
access status of papers so that there is
no influence on editorial decisions
9 Authors pay an Article Processing Charge
(APC) of US$3,000 upon acceptance
9 Open access articles are then published
online-only, and are freely available on
AdisOnline.com and Ovid to read, copy,
share and distribute for non-commercial
purposes
Adis Rapid
Publishing
Service
9 An optional service for
any submitted original
research article
9 7-10 working days peer review guaranteed
9 Publish in a choice of well-established
journals in as little as 3-4 weeks
9 Rigorous assessment by Editors and
external peer reviewers
9 Small fee to cover fast-track
administration costs
Adis Drug Evaluations
& Drug Profiles
9 Comprehensive
single-agent reviews,
highlighting the unique
clinical benefits of
a drug
9 Independently researched and expertly
written by skilled Adis writers
9 Peer reviewed externally by therapy
area experts
9 Written to country-specific labelling
where appropriate
9 Timed to maximize clinical relevance and
topicality for the healthcare community
9 Remind healthcare professionals of the
wealth of best evidence supporting a
product’s place in therapy
Introduction Life after publication AdisOnline.com
9 Articles published in Adis journals
appear on AdisOnline.com, a modern
well-established journal platform
with high volumes of traffic
9 Adis articles are also
distributed on Ovid and
through many other aggregation
and document delivery platforms
9 AdisOnline is optimized for a perfect
viewing experience on most mobile
devices
9 Articles on AdisOnline are available:
- In HTML and PDF versions
- In EPUB version for e-reader devices
such as iPad
- With a facility to export tables and
figures to PowerPoint
- With hyperlinks to referenced articles
- In URL formats that are easily located
by search engines and library systems
- With a facility to attach Supplementary
Digital Content to the article which
could be as simple as an appendix of
data tables, or as complex as a video
or podcast (e.g. author commentary)
Article usage reports
These reports are available on request after
an article is published on AdisOnline. They use
WebTrends data to show the number of times
an article has been viewed since publication.
They also provide a ranking of those article
views versus all the other articles viewed in
that journal during the same period.
Digital eprints
Adis uses the latest digital book technology
and digital rights management, providing
flexible eprint solutions with ROI metrics
to meet a wide range of communication
objectives.
� �
General Medicine
Drugs
Premier journal,
publishing pivotal
phase 3 research
and seminal reviews
CDI
Ideal vehicle for
supporting studies
Drugs in R&D
A fully open access
journal for supporting
research and reviews
PharmacoEconomics
Premier health
economics journal
Applied Health Economics
and Health Policy
Sister journal to
PharmacoEconomics
with a broader scope
The Patient:
Publishes studies of
patient preferences and
patient-centered outcomes
Health Outcomes
Pediatric Drugs
Rapid journal publication
is becoming increasingly
important with European
requirements to post
pediatric study results in
EudraCT database within
6 months of completion
Drugs & Aging
Increasingly important
area as older population
grows
Special Patient Populations
Cardiology, CNS, and DermatologyA strong presence in selected
therapy areas
Special DisciplinesIndustry-leading titles in key areas
of drug development
Therapy area strengths
� �
Permissions required to reproduce
or adapt material
Authors must acknowledge and seek
the appropriate permissions to use all
text, illustrations, and tables adapted or
reproduced from other publications.
Duplicate publication and
duplicate submission
Manuscripts are considered with the
understanding that they have not been
published previously and are not under
consideration by another publication.
Clinical trial registration
With the exception of Clinical Drug
Investigation all Adis journals require,
as a condition of consideration of original
clinical research for publication, prospective
registration of clinical trials in a public
trials registry before recruitment of any
participants. This applies to trials which
commenced after 1 July 2005: for older trials
retrospective registration will be acceptable,
but only if completed before submission of
the manuscript to the journal.
Copyright
Unless their article is published under an
open access license, authors will be asked
to sign a transfer of copyright agreement,
which recognizes the common interest that
both the journal and author(s) have in the
protection of copyright.
Authorship criteria
Each author should have participated
sufficiently in the submitted work to take
public responsibility for appropriate portions
of the content. Authors should meet all the
following criteria:
9 Conceived and planned the work that
led to the manuscript, and/or played an
important role in the acquisition, analysis,
and interpretation of the data
9 Wrote the paper and/or made substantive
suggestions for revision
9 Approved the final submitted version
The corresponding author takes responsibility
for the work as a whole, from inception to the
published manuscript, and will be responsible
for sign-off of the final proofs prior to
publication.
The corresponding author must provide a
statement indicating the names and
contributions of all persons who have provided
input to the manuscript, but who do not fulfil
authorship criteria. This information will be
published in an Acknowledgments section
of the paper.
Authors should obtain written permission
from individuals to be named in the
Acknowledgments section.
Conflict of Interest Statement for authors
and role of the funding source
To prevent ambiguity, authors must state
explicitly whether potential conflicts do or
do not exist. Both conflicts and the role of
any funding source must be summarized in
the Acknowledgments section of the paper.
Ethical conduct of research
For human or animal experimental
investigations, appropriate institutional
review board approval is required, and/or
the principles Declaration of Helsinki should
be followed.
Protection of patients’ rights to privacy
Identifying information should not be
included in written descriptions, photographs,
and pedigrees unless the information is
essential for scientific purposes and the
patient gives written informed consent
for publication.
Use of personal communications and
unpublished data
Authors must include a signed statement
of permission from each individual
identified as a source of information in a
personal communication or as a source for
unpublished data.
Best publishing practice
Adis Journals is committed to the best ethical
publishing practices, endorsing the ‘Uniform
Requirements for Manuscripts Submitted
to Biomedical Journals’ developed by the
International Committee for Medical Journal
Editors (ICMJE), and is also a member of the
Committee on Publication Ethics (COPE),
observing their Code of Conduct and Best
Practice Guidelines for Journal Editors.
The full Adis policies for each journal are
available for review on AdisOnline.
The key requirements for authors are
as follows:
� �
USA
North America and East Coast
Garrett R. Groesbeck
Tel: +1 ��� ��� 91�1
Email: garrett.groesbeck@springer.com
North America, Midwest and West Coast
Philip E. Thoman
Tel: +1 ��� ��1 8���
Email: philip.thoman@springer.com
Contact usTo view Adis journals online go to:
http://adisonline.com
For more information please contact
your local representative, or alternatively:
Europe and Rest of World
Jan Seal-Roberts
Tel: +�� �0� 981 0���
Email: jan.roberts@springer.com
top related